Physician profile
Devin Sessions
NPI 1790104958
$1,600.23
in general payments reported to CMS, 2019-2025
15 companies · $220 in 2025
The $220 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $403 · 2020: $281 · 2021: $33.83 · 2022: $46.78 · 2023: $367 · 2024: $248 · 2025: $220.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $576.70 | 2019-2025 | Pico 7, Renasys Go V2 Home, Grafix Pl |
| Organogenesis INC. | $266.71 | 2019-2024 | Novachor |
| Abbvie INC. | $224.92 | 2023-2025 | |
| Misonix INC | $124.01 | 2019 | |
| Integra Lifesciences Corporation | $93.14 | 2019-2025 | Tcc-Ez |
| Kerecis Limited | $68.71 | 2023-2024 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Kci USA, INC. | $47.22 | 2019-2023 | Activ.A.C., 3m Coban |
| Tactile Systems Technology INC | $47.04 | 2020-2025 | Flexitouch Plus, Nimbl |
| Paratek Pharmaceuticals, INC. | $39.09 | 2022-2023 | Nuzyra |
| Cashflow Solutions, LLC | $28.76 | 2022-2023 | Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt, Pcd-52 737a (US) White |
| Solventum Corporation | $21.54 | 2025 | Activ.A.C., Promogran Prisma |
| Urgo Medical North America, LLC | $19.69 | 2023 | Urgok2, Vashe Wound Solution 250 Ml (8.5 Fl Oz) Flip Top Cap, Drawtex Hydroconductive Wound Dressing With Levafiber 4x4 |
| Mimedx Group, INC. | $16.87 | 2024 | |
| Melinta Therapeutics, LLC | $13.92 | 2025 | Orbactiv, Kimyrsa |
| Glaxosmithkline, LLC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Sessions listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.